Trial Profile

An Open Label, Phase I Study of BI 754091 Monotherapy and Combination Therapy of BI 754091 and BI 754111 in Asian Patients With Advanced Solid Tumours

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 19 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ezabenlimab (Primary) ; Miptenalimab (Primary)
Indications Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Boehringer Ingelheim

Most Recent Events

30 Mar 2024 Results assessing safety, maximum tolerated dose (MTD), pharmacokinetics and antitumour activity of ezabenlimab in Study 1381.1 (NCT02952248), Study 1381.4 (NCT03433898) and Study 1381.3 (NCT03780725) published in the Cancer Immunology Immunotherapy.
27 Jul 2023 Status changed from active, no longer recruiting to completed.
10 Jul 2023 Planned End Date changed from 4 Aug 2023 to 19 Jul 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com